Child Allergy Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Allergic diseases are among the most common chronic conditions of childhood, affecting 30–40% of children in developed countries and increasing in prevalence globally. The paediatric allergic spectrum encompasses IgE-mediated immediate hypersensitivity reactions — food allergy, allergic rhinoconjunctivitis, allergic asthma, and anaphylaxis — as well as non-IgE-mediated and mixed conditions including eczema (atopic dermatitis), eosinophilic oesophagitis, food protein-induced enterocolitis syndrome (FPIES), and contact dermatitis. These conditions frequently co-exist — the 'atopic march' describes the progression from infant eczema through food allergy to allergic rhinitis and asthma in predisposed children.

Paediatric allergy management is a specialist field requiring expertise in both the diagnostic evaluation — including specific IgE testing, skin prick testing, component-resolved diagnostics, and oral food challenges — and the treatment spectrum from allergen avoidance and pharmacotherapy through allergen immunotherapy and emerging biological therapies. Optimal management requires a multidisciplinary team involving paediatric allergists, dermatologists, dietitians, and respiratory physicians, working in partnership with families who bear the primary burden of allergy management at home and school.

The goals of treatment are: accurate diagnosis with identification of specific allergenic triggers; reduction of allergic symptoms and prevention of acute reactions; prevention of anaphylaxis through patient and carer education and adrenaline auto-injector (EpiPen) training; and where possible, modification of the underlying allergic immune response through allergen immunotherapy — the only disease-modifying treatment available.

Food allergy — particularly to cow's milk, hen's egg, peanut, tree nuts, wheat, soy, sesame, fish, and shellfish — affects approximately 5–8% of children under five years in Western countries. IgE-mediated food allergy causes symptoms ranging from urticaria and angioedema to anaphylaxis (life-threatening systemic reaction with cardiovascular or respiratory compromise) within minutes to two hours of food ingestion. Non-IgE-mediated food reactions cause delayed gastrointestinal symptoms (FPIES, FPIES enteropathy). Peanut allergy — the leading cause of food-related anaphylaxis — persists into adulthood in 80% of affected children, unlike milk and egg allergy which resolve in the majority by school age.

Allergic rhinitis (hay fever) from house dust mite, tree and grass pollen, or animal dander causes chronic nasal congestion, sneezing, rhinorrhoea, and postnasal drip, significantly impairing sleep and school performance. Allergic rhinitis is the most prevalent paediatric allergic condition globally. Atopic dermatitis (eczema) affects 15–20% of children and involves chronic, relapsing, intensely itchy inflammatory skin disease driven by barrier dysfunction and type 2 immune skewing. Drug allergy — particularly to penicillin and other beta-lactam antibiotics — is frequently suspected but rarely confirmed on formal challenge testing; most children labelled 'penicillin-allergic' are not on challenge.

Children with suspected allergic disease should be referred to a paediatric allergist when: symptoms are severe or poorly controlled despite first-line treatment; anaphylaxis has occurred or is suspected; the diagnosis is uncertain; allergen immunotherapy is being considered; or the allergic condition is significantly affecting quality of life, sleep, growth, school attendance, or psychological wellbeing. Earlier specialist assessment is preferable to late referral — oral food challenges under medical supervision are essential to confirm or refute food allergy diagnoses and should not be delayed, as prolonged unnecessary dietary exclusion can impair nutrition and quality of life.

Food challenges and allergen immunotherapy are not appropriate for children with uncontrolled asthma (too high a risk of severe reaction), active eczema with significantly compromised skin barrier, or those receiving beta-blockers or ACE inhibitors that impair anaphylaxis treatment efficacy. Children with severe combined immunodeficiency or other primary immunodeficiency conditions require specialist allergy assessment but may have modified treatment protocols. Age is not a contraindication to allergen immunotherapy — children as young as five years can begin sublingual or subcutaneous immunotherapy for house dust mite or grass pollen allergy.

Allergen avoidance is the cornerstone of management for confirmed food allergy — complete avoidance of the allergenic food with robust labelling literacy, emergency action planning, and adrenaline auto-injector prescription and training. NICE and WAO guidelines recommend that all children with confirmed IgE-mediated food allergy at risk of anaphylaxis carry two adrenaline auto-injectors (EpiPen, Jext) at all times. Adrenaline intramuscular 0.01 mg/kg (maximum 0.5 mg) administered into the outer thigh is the first-line treatment for anaphylaxis.

Pharmacotherapy for allergic rhinitis follows a stepwise approach: intranasal corticosteroids (fluticasone, mometasone, triamcinolone) are the most effective first-line treatment for moderate-severe persistent rhinitis; non-sedating antihistamines (loratadine, cetirizine, desloratadine) control intermittent mild symptoms; leukotriene receptor antagonists (montelukast) provide modest additional benefit particularly when rhinitis coexists with asthma. Allergen immunotherapy (AIT) — subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT) — is the only disease-modifying treatment that changes the underlying allergic immune response. AIT with grass pollen, house dust mite, or animal dander reduces rhinitis symptom scores by 30–40% and prevents the development of new allergen sensitivities and asthma in atopic children. Oral immunotherapy (OIT) for peanut allergy — standardised peanut protein (Palforzia) approved by FDA and EMA — desensitises peanut-allergic children to reduce anaphylaxis risk from accidental exposure.

Allergen immunotherapy for allergic rhinitis produces clinically and statistically significant symptom reduction of 30–50% compared to placebo in controlled trials, with reduced medication use and improved quality of life measures persisting for three to seven years after completing a three-year course — a durable disease-modifying effect not seen with symptomatic medications. AIT also reduces the risk of developing asthma in rhinitis-only children by 30–50% at long-term follow-up, and prevents new allergen sensitisations developing.

For peanut oral immunotherapy with Palforzia, the PALISADE trial demonstrated that 67% of treated children aged 4–17 tolerated a single dose of 600 mg peanut protein (equivalent to approximately two peanuts) without severe symptoms compared to 4% of placebo recipients — providing meaningful protection from accidental low-dose exposure, the most common real-world scenario leading to paediatric anaphylaxis. Quality of life improvements for both child and family are significant: reduced hypervigilance, improved social participation (school meals, birthday parties, eating out), and reduced anxiety, all of which are profoundly impaired in families managing peanut and multi-food allergy. Natural history of cow's milk and egg allergy is favourable — approximately 70–80% of children achieve spontaneous tolerance by age six to eight years with appropriate managed reintroduction using milk and egg 'ladders'.

Allergen immunotherapy carries a risk of allergic reactions during treatment — local reactions (swelling and itching at the subcutaneous injection site or oral mucosal tingling with SLIT) are common and expected. Systemic reactions — urticaria, angioedema, bronchospasm — occur in approximately 0.1–0.5% of SCIT injections and are managed with antihistamines or, for severe reactions, adrenaline. Anaphylaxis to SCIT injections occurs in approximately 1 in 1,000,000 injections at experienced centres with 30-minute post-injection observation. Risk is higher during updosing phases and is minimised by withholding treatment during asthma exacerbations or systemic illness.

Adrenaline auto-injector use in schools — the most common setting for paediatric allergic reactions — requires robust anaphylaxis action plans, training of teachers and school staff, and immediate emergency service access. Under-use of adrenaline (using antihistamines instead as first-line treatment) is the most common error in managing paediatric anaphylaxis and a major contributor to preventable fatal outcomes. Prolonged avoidance diets — particularly when cow's milk is excluded without dietitian guidance — can lead to calcium deficiency, vitamin D deficiency, and growth restriction in young children. Dietary management of food allergy requires specialist dietitian input to ensure nutritional adequacy.

Children with food allergy require regular allergy reviews — typically annually — for repeat skin prick testing or specific IgE measurement to assess whether natural tolerance has developed and whether supervised oral food challenge is appropriate to reintroduce the food. Early, supervised reintroduction at the earliest opportunity improves quality of life and nutritional status. Children with allergic rhinitis on SCIT receive injections weekly during the updosing phase (four to twelve months) then monthly during the maintenance phase for a total treatment duration of three years. SLIT drops or tablets are administered daily at home, with monthly or quarterly clinic review.

School anaphylaxis action plans are reviewed and updated annually; adrenaline auto-injector prescriptions are renewed with updated weight-based dosing as the child grows. Adolescence is a particularly high-risk period for allergic reactions from risk-taking behaviour, decreased adherence to dietary avoidance, reduced compliance with carrying adrenaline auto-injectors, and peer pressure at social events. Transition from paediatric to adult allergy services at age sixteen to eighteen requires careful planning to maintain continuity of management and transfer of the patient's allergy action plan and immunotherapy records.

Paediatric allergy diagnosis and management is available through NHS or public health systems in the UK, Europe, and Australia at no direct charge for qualifying children, but waiting times for specialist paediatric allergist appointments can be long (twelve to twenty-four months in some regions). Private paediatric allergy consultations in the UK cost GBP 200–500; allergy testing GBP 200–400; a three-year SCIT immunotherapy course GBP 5,000–15,000. In the US, specialist paediatric allergy evaluation and skin testing costs USD 300–600; immunotherapy injections USD 1,500–4,000 per year.

In India, private paediatric allergy clinics at Apollo Hospitals, Manipal Hospitals, Kokilaben Dhirubhai Ambani Hospital, and specialist allergy centres offer comprehensive allergy testing and diagnosis for USD 150–400, and allergen immunotherapy programmes for USD 600–2,000 per year — representing savings of 70–85% versus US private prices. Thailand (Bumrungrad, Ramathibodi Hospital) charges USD 300–600 for comprehensive allergy evaluation. For families residing in countries without access to specialist paediatric allergists — particularly in South Asia, Southeast Asia, and the Middle East — accessing specialist allergy evaluation at a high-quality regional centre represents significant practical value.

Dupilumab (Dupixent) — a biologic antibody blocking IL-4 and IL-13 signalling — is licensed for moderate-to-severe atopic dermatitis in children from six months of age and significantly reduces eczema severity, pruritus, and sleep disturbance, with a favourable safety profile. Biologics are an important alternative for eczema not adequately controlled with topical therapy. For severe allergic asthma with type 2 inflammation, anti-IgE therapy (omalizumab) and anti-IL-5 biologics are available for children above six years. Elemental amino acid-based formula substitution is the treatment for cow's milk protein allergy in formula-fed infants, replacing standard cow's milk formula entirely.

Complementary and alternative medicine (CAM) approaches — herbal medicine, acupuncture, homeopathy, diet exclusion beyond confirmed allergens — have no established evidence of efficacy in paediatric allergy from controlled trials and carry risks of nutritional deficiency, delayed evidence-based treatment, and rare serious adverse events from unlicensed herbal products. Families should be counselled that these approaches are not substitutes for evidence-based allergy evaluation and management.